BIEL + Viant + VLMS = $$$
The Smart Relief Alliance with Exponential ROI Potential
Bitcoin delivered a ~40,000% return over the last decade. Now, BioElectronics Corporation (BIEL)—fueled by real products, strategic execution, and equity-driven partnerships—is positioned to deliver comparable performance. And it’s happening through something radically simple: open-market share accumulation.
Viant Medical and VLMS Global Healthcare aren’t just collaborators. They're growth-stage equity partners building this trajectory from the ground up.
Public Shares Create the Simplest Strategic Partnership
Forget M&A drama and cap table negotiations. Viant and VLMS became equity-aligned stakeholders simply by acquiring BIEL stock, turning backend success into compounding wealth:
Equity stakes scale with each operational win
No dilution, no restructuring—just performance-based value creation
Execution and shareholding go hand-in-hand
It's frictionless, transparent, and ready for replication.
BIEL's Path to Exponential ROI
Every step Viant and VLMS take—expanding reimbursement, manufacturing devices, or opening new markets—pushes the PPS higher and fuels shareholder returns.
Here’s how the surge unfolds:
Early breakout phase: BIEL leaves the sub-penny range ("trips"
when market hints emerge—like technical indicators (Golden Cross at $0.0004, Blue Sky Breakout at $0.0005) triggered by news of strategic deals.
First viral surge: At PPS = $0.003 (a 3,000% increase), headlines compare BIEL’s ROI with Apple and Amazon over 10 years. The buzz builds. Retail energy ignites. Visibility explodes.
Quarterly catalyst: A $400,000 revenue quarter or a projected $1.5M in annual revenue positions BIEL toward copper ($0.01)—a 10,000% increase.
Profit traction: Reach $10M in profits and PPS hits $0.04—mirroring Bitcoin’s 40,000% ROI.
Full market momentum: $25M in profit sends PPS toward $0.10—a 100,000% return.
And for equity partners holding shares from early stages? The compounding is historic.
Viant + VLMS Drive the Metrics That Matter
VLMS activates global reimbursement infrastructure. Their coding wins = revenue growth = PPS lift.
Viant delivers scalable, compliant hardware to meet exploding demand. Their fulfillment = valuation growth = shareholder gain.
Their results show up on income statements and in portfolio statements.
Tax-Efficient Profitability + Retail Catalyst
BIEL’s lean OEM model and low operating costs mean profitability is within reach—even modest revenue can push PPS out of the trips. Plus:
$40M tax-loss carryforward means early profits are tax-free
Viral press at PPS = $0.003 could create a GameStop-like surge
Share buybacks after loan payoff would accelerate valuation climbs
Every media mention of Viant and VLMS as equity partners compounds credibility—and investor enthusiasm.
Final Thought: Execute. Accumulate. Prosper.
Viant builds devices. VLMS powers payer access. BIEL delivers scalable healing. And by acquiring BIEL shares, Viant and VLMS own the outcomes they create.
✅ No barriers ✅ No dilution ✅ Direct path from execution to exponential return
Welcome to Smart Relief Alliance 360—where strategic equity turns medical innovation into legacy-level wealth.
The Smart Relief Alliance with Exponential ROI Potential
Bitcoin delivered a ~40,000% return over the last decade. Now, BioElectronics Corporation (BIEL)—fueled by real products, strategic execution, and equity-driven partnerships—is positioned to deliver comparable performance. And it’s happening through something radically simple: open-market share accumulation.
Viant Medical and VLMS Global Healthcare aren’t just collaborators. They're growth-stage equity partners building this trajectory from the ground up.
Public Shares Create the Simplest Strategic Partnership
Forget M&A drama and cap table negotiations. Viant and VLMS became equity-aligned stakeholders simply by acquiring BIEL stock, turning backend success into compounding wealth:
Equity stakes scale with each operational win
No dilution, no restructuring—just performance-based value creation
Execution and shareholding go hand-in-hand
It's frictionless, transparent, and ready for replication.
BIEL's Path to Exponential ROI
Every step Viant and VLMS take—expanding reimbursement, manufacturing devices, or opening new markets—pushes the PPS higher and fuels shareholder returns.
Here’s how the surge unfolds:
Early breakout phase: BIEL leaves the sub-penny range ("trips"
when market hints emerge—like technical indicators (Golden Cross at $0.0004, Blue Sky Breakout at $0.0005) triggered by news of strategic deals. First viral surge: At PPS = $0.003 (a 3,000% increase), headlines compare BIEL’s ROI with Apple and Amazon over 10 years. The buzz builds. Retail energy ignites. Visibility explodes.
Quarterly catalyst: A $400,000 revenue quarter or a projected $1.5M in annual revenue positions BIEL toward copper ($0.01)—a 10,000% increase.
Profit traction: Reach $10M in profits and PPS hits $0.04—mirroring Bitcoin’s 40,000% ROI.
Full market momentum: $25M in profit sends PPS toward $0.10—a 100,000% return.
And for equity partners holding shares from early stages? The compounding is historic.
Viant + VLMS Drive the Metrics That Matter
VLMS activates global reimbursement infrastructure. Their coding wins = revenue growth = PPS lift.
Viant delivers scalable, compliant hardware to meet exploding demand. Their fulfillment = valuation growth = shareholder gain.
Their results show up on income statements and in portfolio statements.
Tax-Efficient Profitability + Retail Catalyst
BIEL’s lean OEM model and low operating costs mean profitability is within reach—even modest revenue can push PPS out of the trips. Plus:
$40M tax-loss carryforward means early profits are tax-free
Viral press at PPS = $0.003 could create a GameStop-like surge
Share buybacks after loan payoff would accelerate valuation climbs
Every media mention of Viant and VLMS as equity partners compounds credibility—and investor enthusiasm.
Final Thought: Execute. Accumulate. Prosper.
Viant builds devices. VLMS powers payer access. BIEL delivers scalable healing. And by acquiring BIEL shares, Viant and VLMS own the outcomes they create.
✅ No barriers ✅ No dilution ✅ Direct path from execution to exponential return
Welcome to Smart Relief Alliance 360—where strategic equity turns medical innovation into legacy-level wealth.
2
